PROTAGONIST THERAPEUTICS INC's ticker is PTGX and the CUSIP is 74366E102. A total of 65 filers reported holding PROTAGONIST THERAPEUTICS INC in Q1 2019. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2020 | $212,000 | -9.0% | 10,867 | -17.6% | 0.02% | -8.0% |
| Q2 2020 | $233,000 | +65.2% | 13,189 | -23.0% | 0.02% | +108.3% |
| Q1 2020 | $141,000 | +18.5% | 17,122 | +1.0% | 0.01% | +20.0% |
| Q4 2019 | $119,000 | -46.4% | 16,947 | -8.4% | 0.01% | -47.4% |
| Q3 2019 | $222,000 | -9.4% | 18,511 | -8.6% | 0.02% | -9.5% |
| Q2 2019 | $245,000 | -5.4% | 20,244 | -1.7% | 0.02% | 0.0% |
| Q1 2019 | $259,000 | +46.3% | 20,599 | -21.8% | 0.02% | +50.0% |
| Q4 2018 | $177,000 | -50.1% | 26,335 | -29.4% | 0.01% | -36.4% |
| Q3 2018 | $355,000 | +50.4% | 37,299 | +6.2% | 0.02% | +57.1% |
| Q2 2018 | $236,000 | – | 35,133 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 2,449,183 | $20,647,000 | 6.08% |
| Bain Capital Life Sciences Investors, LLC | 2,260,572 | $19,057,000 | 2.28% |
| Kynam Capital Management, LP | 519,212 | $4,377,000 | 0.92% |
| RTW INVESTMENTS, LP | 4,176,837 | $35,211,000 | 0.81% |
| Tri Locum Partners LP | 199,500 | $1,682,000 | 0.46% |
| Birchview Capital, LP | 38,000 | $320,000 | 0.22% |
| Gratus Capital, LLC | 206,113 | $1,738,000 | 0.18% |
| FARALLON CAPITAL MANAGEMENT LLC | 3,651,887 | $30,785,000 | 0.17% |
| PDT Partners, LLC | 126,038 | $1,063,000 | 0.16% |
| FOX RUN MANAGEMENT, L.L.C. | 40,683 | $343,000 | 0.13% |